Table 1. Demographic and clinical characteristics of those with improved, stable, and declining eGFR slope.
| Overall | Improved eGFR slope | Stable eGFR slope | Declining eGFR slope | |
|---|---|---|---|---|
| Number (%) | 204,132 | 41,410 (20.29) | 111,554 (54.65) | 51,168 (25.07) |
| Age (SD) | 70.93 (7.82) | 69.48 (8.53) | 71.12 (7.71) | 71.68 (7.28) |
| Race | ||||
| White (%) | 178,774 (87.58) | 35,481 (85.68) | 98,926 (88.68) | 44,367 (86.71) |
| Black (%) | 21,785 (10.67) | 5,205 (12.57) | 10,741 (9.63) | 5,839 (11.41) |
| Other (%) | 3,573 (1.75) | 724 (1.75) | 1,887 (1.69) | 962 (1.88) |
| Male Gender (%) | 195,597 (95.82) | 39,293 (94.89) | 106,822 (95.76) | 49,482 (96.70) |
| Cerebrovascular Disease (%) | 2,070 (1.01) | 400 (0.97) | 873 (0.78) | 797 (1.56) |
| Cardiovascular Disease (%) | 99,842 (48.91) | 19,772 (47.75) | 49,922 (44.75) | 30,148 (58.92) |
| Dementia (%) | 9,447 (4.63) | 2,212 (5.34) | 4,346 (3.90) | 2,889 (5.65) |
| Diabetes Mellitus (%) | 74,972 (36.73) | 14,639 (35.35) | 34,708 (31.11) | 25,625 (50.08) |
| Hepatitis C (%) | 3,025 (1.48) | 816 (1.97) | 1,216 (1.09) | 993 (1.94) |
| HIV (%) | 12,474 (6.11) | 2,991 (7.22) | 5,640 (5.06) | 3,843 (7.51) |
| Hypertension (%) | 174,481 (85.47) | 35,073 (84.70) | 92,335 (82.77) | 47,073 (92.00) |
| Hyperlipidemia (%) | 148,537 (72.77) | 29,554 (71.37) | 80,107 (71.81) | 38,876 (75.98) |
| Chronic Lung Disease (%) | 49,848 (24.42) | 11,283 (27.25) | 23,921 (21.44) | 14,644 (28.62) |
| Peripheral Artery Disease (%) | 11,045 (5.41) | 2,166 (5.23) | 4,486 (4.02) | 4,393 (8.59) |
| Death (%) | 89,156 (43.68) | 17,519 (42.31) | 42,350 (37.96) | 29,287 (57.24) |
| Average eGFR slope before T0 ml/min/1.73m2/year * (SD) | -0.57 (3.84) | 4.01 (3.36) | -0.36 (1.67) | -4.76 (2.99) |
| Average initial eGFR in ml/min/1.73m2 (SD) | 53.90 (4.17) | 53.18 (4.30) | 54.05 (4.10) | 54.17 (4.14) |
| Average T0 eGFR in ml/min/1.73m2 (SD) | 52.71 (11.22) | 64.18 (10.29) | 53.50 (6.72) | 41.70 (9.44) |
| Median duration between initial and T0 eGFR in years (IQR) | 3.38 (2.18, 4.23) | 3.51 (2.43, 4.26) | 3.11 (1.94, 4.08) | 3.78 (2.70, 4.42) |
| Median number of eGFR measure before T0 (IQR) | 7 (4, 12) | 8 (5, 12) | 6 (4, 10) | 10 (6, 16) |
| Median number of eGFR measure after T0 (IQR) | 13 (7, 21) | 13 (7, 21) | 12 (6, 20) | 13 (6, 23) |
| Weight | ||||
| Number | 185,508 | 38,997 | 99,376 | 47,135 |
| Average Annual change lb/year (SD) | -0.59 (10.87) | -1.20 (7.01) | -0.45 (9.42) | -0.39 (15.39) |
| Median Annual percentage change (IQR) | -0.26% (-1.44%, -0.90%) | -0.47% (-1.76%, -0.72%) | -0.22% (-1.34%, -0.89%) | -0.18% (-1.40%, -1.07%) |
| Micro albumin / Creatinine Ratio | ||||
| Number | 63,021 | 12,792 | 33,094 | 17,135 |
| Normal (%) | 35,369 (56.12) | 7,716 (60.32) | 19,531 (59.02) | 8,122 (47.40) |
| Mild (%) | 23,376 (37.09) | 4,455 (34.83) | 11,781 (35.60) | 7,140 (41.67) |
| Severe (%) | 4,276 (6.79) | 621 (4.85) | 1,782 (5.38) | 1,873 (10.93) |
*Reflects the rate of change of eGFR per year calculated using a Bayesian mixed effect model. The slope of the regression line describes the rate of change in kidney function (eGFR) over time.